A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF ABP 959 COMPARED WITH ECULIZUMAB IN ADULT SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) - ABP 959 in PNH

Amgen Inc.0 个研究点目标入组 40 人开始时间: 2018年12月11日最近更新: 2019年6月30日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 40

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

入选标准

•The study will enroll participants with PNH who are stable on eculizumab treatment. All inclusion criteria must be met.
•1. Men and women = 18 years of age
•2. Historical diagnosis of PNH by documented flow cytometry (e.g., type III erythrocyte cells of = 10%)
•3. Administration of eculizumab for = 6 months and currently receiving 900 mg of eculizumab every 14 ± 2 days
•4. Haemoglobin = 9.0 g/dL for at least 6 weeks prior to randomisation
•5. Lactate dehydrogenase (LDH) < 1.5 × the upper limit of normal at screening
•6. Platelet count = 50 × 1 09/L
•7. Absolute neutrophil (a type of white blood cell) count = 0.5 x 1 09/L (500/µL)
•8. Participants must have been vaccinated against Neisseria meningitidis (meningococcus – a bacteria which causes meningitis). Participants must be vaccinated or revaccinated according to current national guidelines for vaccination use.
•9. Participants must sign an independent ethics committee-approved informed consent form before participation in any procedures.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 35
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

排除标准

•If any of the following apply, the subject MUST NOT enter the study:
•1. Known or suspected hereditary complement deficiency
•2. Clinically significant cardiovascular disease (including myocardial infarction (heart attack), unstable angina, symptomatic congestive heart failure [New York Heart Association = Class III], serious uncontrolled cardiac arrhythmia), peripheral vascular disease (a blood circulation disorder), cerebrovascular accident (stroke), or transient ischemic attack (mini stroke) in the previous 6 months
•3. Evidence of acute thrombosis (liver Doppler ultrasound of hepatic and portal veins)
•4. Known to be positive for human immunodeficiency virus (HIV)
•5. Women who are pregnant or breastfeeding
•6. Women of childbearing potential who does not consent to use a highly effective method of birth control (eg, true abstinence, sterilisation, birth control pills, Depo Provera injections, or contraceptive implants) during treatment and for an additional 5 months after the last administration of protocol-specified treatment
•WOCBP is defined as a woman who is fertile, following menarche, and until becoming postmenopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy, and bilateral
•oophorectomy.
•A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT).
•However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
•Females on HRT and whose menopausal status is in doubt will be required to use 1 of the non-hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
•7. Males with partners of childbearing potential who do not consent to use a highly effective method of birth control (eg, true abstinence, vasectomy, or a condom in combination with hormonal birth control or barrier methods used by the woman) during treatment and for an additional 5 months after the last administration of protocol-specified treatment
•8. Participant is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s), or the participant is receiving other investigational agent(s).
•9. Particpant has known sensitivity to any constituent of the products to be administered during the study, including mammalian cell-derived products.
•10. History or evidence of clinically significant disorder, infection, condition, or disease that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
•11. History of meningococcal infection
•12. Presence or suspicion of active bacterial infection, or recurrent bacterial infection
•13. History of bone marrow transplantation
•14. Red blood cell transfusion required within

研究者

发起方

Amgen Inc.

相似试验

进行中（未招募）

1 期

This trial is designed to determine what effects the investigational medicine, ABP 959, has on the human body, and what effects the body has on theinvestigational medicine after you have been given it, and if this iscomparable to what is seen for the licensed medicine, eculizumab, inpatients with Paroxysmal Nocturnal Hemoglobinuria (PNH).This study will assess if the investigational medicine is safe and effective intreating PNH compared to the licensed medicine.

EUCTR2017-001418-27-ESAmgen Inc.42

进行中（未招募）

1 期

EUCTR2017-001418-27-IEAmgen Inc.40

进行中（未招募）

1 期

EUCTR2017-001418-27-FIAmgen Inc.40

进行中（未招募）

1 期

This trial is designed to determine what effects the investigational medicine, ABP 959, has on the human body, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, eculizumab, in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). This study will assess if the investigational medicine is safe and effective in treating PNH compared to the licensed medicine.Paroxysmal Nocturnal Hemoglobinuria (PNH)MedDRA version: 20.0 Level: LLT Classification code 10055629 Term: Paroxysmal nocturnal hemoglobinuria System Organ Class: 100000004857

EUCTR2017-001418-27-NLAmgen Inc.40

进行中（未招募）

1 期

EUCTR2017-001418-27-CZAmgen Inc.40